Tango Therapeutics TNGX Payments Of Stock Issuance Costs
Payments Of Stock Issuance Costs at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's payments of stock issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's payments of stock issuance costs?
- Tango Therapeutics (TNGX) reported payments of stock issuance costs of $537K in Q1 2026.
- How has Tango Therapeutics's payments of stock issuance costs changed year-over-year?
- Tango Therapeutics's payments of stock issuance costs increased by 5866.7% year-over-year, from $9K to $537K.
- What does payments of stock issuance costs mean?
- Represents the direct costs incurred in the process of issuing new equity, such as underwriting fees, legal fees, and registration expenses. These costs are deducted from the gross proceeds of equity offerings. Monitoring these costs helps assess the efficiency of the company's capital-raising activities.